Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Dyslipidemia

Dyslipidemia

24 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Dyslipidemia

72 trials tracked for Dyslipidemia: 33 in phase 3 or 4 and 7 with published results. The most-cited published study has 488 citations.

72Trials tracked
33Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 7 Phase 3 26 Phase 2 15 Phase 1 6 Other / NA 18
  1. Phase 3 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects Completed · 488 cited
  2. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension Completed · 405 cited
  3. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed · 185 cited
  4. Phase 4 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed · 127 cited
  5. Phase 4 Effects of Metformin on Hepatic FFA Metabolism Completed · 65 cited
  6. Phase 4 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed · 11 cited
Show 44 more trials
  1. Phase 3 Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia Completed · 7 cited
  2. Phase 4 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients Completed
  3. Phase 4 A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects Completed
  4. Phase 4 A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk Completed
  5. Phase 4 Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels Completed
  6. Phase 3 Fenofibrate Treatment in SCI Completed
  7. Phase 3 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia Completed
  8. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  9. Phase 3 A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia Completed
  10. Phase 3 Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors Completed
  11. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  12. Phase 3 Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  13. Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Completed
  14. Phase 3 A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease Completed
  15. Phase 3 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Completed
  16. Phase 3 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease Completed
  17. Phase 3 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Completed
  18. Phase 3 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed
  19. Phase 3 Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels Completed
  20. Phase 3 Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin Completed
  21. Phase 3 Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia Completed
  22. Phase 3 Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes Completed
  23. Phase 3 Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  24. Phase 3 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood Completed
  25. Phase 3 Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia Completed
  26. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  27. Phase 3 A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) Completed
  28. Phase 2 Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study Completed
  29. Phase 2 ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study Completed
  30. Phase 2 A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides Completed
  31. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia Completed
  32. Phase 2 A Study of AZD8233 in Participants With Dyslipidemia. Completed
  33. Phase 2 Preliminary Study of Safety and Efficacy of Policosanol Completed
  34. Phase 2 Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes Completed
  35. Phase 2 A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins Completed
  36. Phase 2 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Completed
  37. Phase 2 A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) Completed
  38. Phase 2 A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) Completed
  39. Phase 2 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C Completed
  40. Phase 2 A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins Completed
  41. Phase 2 Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR Completed
  42. Phase 2 Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia Completed
  43. Phase 1 Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia Completed
  44. Phase 1 MK0524B Bioequivalence Study (0524B-070) Completed

Showing the 50 most-cited and recently-updated of 72 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Dyslipidemia: what the trials found

Several statin and combination therapies demonstrated significant efficacy in lipid management. Alirocumbar reduced non-HDL-C by 37.3% (p<0.0001) and LDL-C by 43.3% (p<0.0001) 1. Pitavastatin showed consistent reductions in LDL-C of approximately 40-44% [21, 22] and was effective in patients with HIV-related dyslipidemia 3. Combination therapies also showed results: Rosuvastatin plus Ezetimibe reduced LDL-C by 29.13% to 39.45% (p=0.0013) 11, while a Fenofibrate/simvastatin combination significantly increased HDL-C and reduced LDL-C in several cohorts 14.

Specific lipid markers were modified by other agents: Fenofibrate showed a 40% reduction in triglycerides 13, and the addition of ABT-335 to rosuvastatin resulted in significant increases in HDL-C (23.0%) and reductions in both triglycerides (-40.3%) and LDL-C (-28.7%) 18. Additionally, ABT-335 plus rosuvastatin showed a 38% reduction in triglycerides and a 16.9% increase in HDL-C over 8 weeks 19.

Evolocumab demonstrated significant lipid lowering, with LDL-C reductions of approximately 56-59% across multiple cohorts 9, and significantly improved outcomes for cardiovascular death, myocardial infarction, and stroke (p<0.0001) 10. Other interventions included Omega-3 fatty acids which reduced triglycerides by 34% (p=0.01) 4, and Amlodipine besylate, which showed significant improvements in blood pressure and LDL-C targets at weeks 4 and 6 (p<0.001) 6.

Other interventions included Metformin 2, Plant sterols esters 7, LCP-AtorFen 12, and MCI-196 15.

For the clinician treating this condition

  • Evolocumab provides robust LDL-C reduction (approx. 58%) and significant reductions in major cardiovascular events including myocardial infarction and stroke.
  • Pitavastatin is effective for LDL-C reduction (approx. 40-44%) and specifically useful in populations with HIV-related dyslipidemia.
  • Combination therapies, such as Rosuvastatin/Ezetimibe or Fenofibrate/simvastatin, are effective for multi-target lipid management including HDL-C and triglyceride reduction.
  • ABT-335 combined with rosuvastatin significantly improves the lipid profile by increasing HDL-C and decreasing both LDL-C and triglycerides.

AI synthesis of 15 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Metabolic syndrome affects 21.3% of Nepalese adults but extreme heterogeneity limits national estimates
Cardiology Meta-analysis
Metabolic syndrome affects 21.3% of Nepalese adults but extreme heterogeneity limits national estimates New data reveals high rates of metabolic syndrome in Nepal
This meta-analysis estimates metabolic syndrome prevalence among Nepalese adults at 21.3%, with low HDL (64.5%) and abdominal obesity (59.5%…
Over 20 percent of adults in Nepal show signs of metabolic syndrome, a cluster of conditions like high blood pressure and obesity.
medRxiv Sep 12, 2026
Fibrosis-informed markers provide a decision architecture for statin allocation in intermediate-risk MASLD patients
Rheumatology Guideline
Fibrosis-informed markers provide a decision architecture for statin allocation in intermediate-risk MASLD patients New guidelines help doctors choose statins for liver disease patients
This guideline proposes a decision-making framework for statin therapy in the intermediate-risk stratum for patients with MASLD. It utilizes…
Doctors now have a clearer way to decide who needs statin treatment when liver health and heart risk overlap.
Frontiers Aug 30, 2026
Mucocutaneous manifestations serve as diagnostic indicators for various systemic diseases and paraneoplastic syndromes
Rheumatology Guideline
Mucocutaneous manifestations serve as diagnostic indicators for various systemic diseases and paraneoplastic syndromes Skin and Mouth Signs May Signal Serious Internal Diseases
This narrative review synthesizes the clinical significance of mucocutaneous signs as indicators for conditions including SLE, dermatomyosit…
Certain skin and mouth changes can serve as important clues for doctors to identify underlying conditions like lupus, infections, and metabo…
Frontiers Aug 16, 2026
Patients with central centrifugal cicatricial alopecia show high prevalence of hypertension and dyslipidemia
Oncology Meta-analysis
Patients with central centrifugal cicatricial alopecia show high prevalence of hypertension and dyslipidemia Common health issues often occur alongside central centrifugal cicatricial alopecia
This meta-analysis of 9103 patients identifies significant comorbidities in central centrifugal cicatricial alopecia (CCCA). Findings includ…
New data shows that people with a specific type of hair loss often deal with other conditions like high blood pressure and anxiety.
Aug 6, 2026
High Intensity Interval Training Improves Cardiometabolic Risk Factors in Pediatric Overweight Populations
Diabetes & Endocrinology Meta-analysis
High Intensity Interval Training Improves Cardiometabolic Risk Factors in Pediatric Overweight Populations High intensity interval training improves heart health in children
Meta-analysis reveals high-intensity interval training significantly improves BMI, blood pressure, and lipid profiles in children with obesi…
High intensity interval training can improve weight, blood pressure, and cholesterol levels for children and teens with overweight or obesit…
Aug 1, 2026
High-intensity interval training reduces body weight and fat mass more than moderate-intensity continuous training
Diabetes & Endocrinology Meta-analysis
High-intensity interval training reduces body weight and fat mass more than moderate-intensity continuous training High intensity interval training improves body composition in college students
This meta-analysis of randomized controlled trials compared high-intensity interval training (HIIT) to moderate-intensity continuous trainin…
High-intensity interval training may help college students lose more fat and weight compared to steady exercise, though it did not change bl…
Frontiers Jul 16, 2026
Adverse Childhood Experiences are associated with increased odds of metabolic syndrome and hyperglycemia
Nutrition & Obesity Medicine Meta-analysis
Adverse Childhood Experiences are associated with increased odds of metabolic syndrome and hyperglycemia Childhood Trauma Linked to Higher Risk of Metabolic Syndrome
This systematic review and meta-analysis of 10 eligible papers found that individuals with at least one Adverse Childhood Experience (ACE) h…
Early childhood trauma is linked to higher risks of high blood pressure, high blood sugar, and other components of metabolic syndrome in adu…
Jul 7, 2026
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Cardiology Sys. Review
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
Frontiers Jun 11, 2026
Preoperative comorbidities linked to reduced weight loss after metabolic and bariatric surgery in adults
Nutrition & Obesity Medicine Meta-analysis
Preoperative comorbidities linked to reduced weight loss after metabolic and bariatric surgery in adults Pre-existing health conditions may slightly reduce weight loss after surgery
A meta-analysis of twenty-three studies reveals that mental illness, diabetes, and sleep apnea are associated with slightly lower weight los…
Adults with mental illness or diabetes before surgery saw slightly less weight loss. Other conditions like high blood pressure did not affec…
Jun 6, 2026
Expert consensus guideline on cholesterol-lowering strategies for Chinese population with dyslipidemia and ASCVD
Drug Pipeline Guideline
Expert consensus guideline on cholesterol-lowering strategies for Chinese population with dyslipidemia and ASCVD New guidelines offer cholesterol strategies for Chinese patients with heart disease
This is an expert consensus guideline for the Chinese population. It synthesizes initial cholesterol-lowering strategies to improve dyslipid…
Experts in China share updated advice to better prevent and manage high cholesterol and artery disease for local patients.
Frontiers May 24, 2026
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Allergy & Immunology Sys. Review
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Frontiers May 21, 2026
Systematic review and meta-analysis shows combined exercise and 16:8 time-restricted eating reduces weight in adults
Nutrition & Obesity Medicine Meta-analysis
Systematic review and meta-analysis shows combined exercise and 16:8 time-restricted eating reduces weight in adults Exercise Plus Time-Restricted Eating Trims Weight Better Than Exercise Alone
This systematic review and meta-analysis evaluated exercise combined with a 16:8 time-restricted eating protocol versus exercise alone in ad…
• Small extra weight and fat loss when fasting meets workouts • Helps adults already exercising regularly • Benefits are modest and short-te…
Frontiers May 14, 2026

Questions about Dyslipidemia

Are there metabolic problems linked to having chronic insomnia while hospitalized?

Yes, chronic insomnia in hospitalized adults is linked to metabolic problems, including elevated fasting blood glucose and dyslipidemia.

Full answer →
What blood proteins might help predict disease progression in people with cardiometabolic conditions?

Proteins like GDF15, ADM, PCSK9, HS-CRP, and S100 proteins may help predict disease progression in people with cardiometabolic conditions.

Full answer →
Does working night shifts cause higher total cholesterol levels in male miners?

Yes, night shift work is linked to higher total cholesterol in male miners, even after accounting for sleep quality, age, and lifestyle factors.

Full answer →
Can high cholesterol levels make kidney disease worse for patients with IgA nephropathy?

Yes, high cholesterol levels can worsen kidney disease in IgA nephropathy patients, as dyslipidemia is linked to poorer renal survival and more severe kidney damage.

Full answer →

All Dyslipidemia Articles